Biomarin Pharmaceutical Inc (NASDAQ: BMRN)’s stock price has decreased by -4.75 compared to its previous closing price of 66.99. However, the company has seen a -4.86% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-01-14 that New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Is It Worth Investing in Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a higher price-to-earnings ratio of 38.42x compared to its average ratio, The 36-month beta value for BMRN is at 0.28. Analysts have varying views on the stock, with 14 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BMRN is 188.22M, and currently, shorts hold a 2.41% of that float. The average trading volume for BMRN on January 15, 2025 was 1.43M shares.
BMRN’s Market Performance
The stock of Biomarin Pharmaceutical Inc (BMRN) has seen a -4.86% decrease in the past week, with a -3.27% drop in the past month, and a -9.30% fall in the past quarter. The volatility ratio for the week is 3.53%, and the volatility levels for the past 30 days are at 2.67% for BMRN. The simple moving average for the past 20 days is -3.82% for BMRN’s stock, with a -17.68% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Wolfe Research repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Wolfe Research is $95 based on the research report published on November 15, 2024 of the previous year 2024.
Raymond James gave a rating of “Outperform” to BMRN, setting the target price at $79 in the report published on October 10th of the previous year.
BMRN Trading at -2.98% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.73% of loss for the given period.
Volatility was left at 2.67%, however, over the last 30 days, the volatility rate increased by 3.53%, as shares sank -3.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.30% lower at present.
During the last 5 trading sessions, BMRN fell by -4.86%, which changed the moving average for the period of 200-days by -27.99% in comparison to the 20-day moving average, which settled at $66.35. In addition, Biomarin Pharmaceutical Inc saw -2.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Guyer Charles Greg, who sale 5,278 shares at the price of $66.37 back on Nov 12 ’24. After this action, Guyer Charles Greg now owns 68,909 shares of Biomarin Pharmaceutical Inc, valued at $350,324 using the latest closing price.
Guyer Charles Greg, the Officer of Biomarin Pharmaceutical Inc, proposed sale 5,278 shares at $66.37 during a trade that took place back on Nov 12 ’24, which means that Guyer Charles Greg is holding shares at $350,324 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.78 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 0.12. The total capital return value is set at 0.05. Equity return is now at value 6.25, with 4.74 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.69. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 19.36.
Currently, EBITDA for the company is 310.28 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.4. The receivables turnover for the company is 3.54for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.27.
Conclusion
In conclusion, Biomarin Pharmaceutical Inc (BMRN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
